Condition

Resectable (2)

Early-stage (1)

NSCLC (1)

Non-metastatic Soft-tissue Sarcoma (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (1)

phase 3 (1)

Sponsor

Institut Bergonie (1)

MedImmune LLC (1)

Collaborator

Chugai Pharma France (1)

Novartis (1)

Intervention

at the discretion of the investigator (1)

danvatirsen (1)

doxorubicin (1)

durvalumab (1)

ifosfamide or dacarbazine (1)

monalizumab (1)

oleclumab (1)

Study Documents

Intervention Type

drug (2)

combination product (1)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

resectable

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Non-metastatic Soft-tissue Sarcoma, Resectable Trial in France (Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the

Recruiting

Non-metastatic Soft-tissue Sarcoma
Resectable

Doxorubicin
+2 more

Bordeaux, France
+9 more

Jul 27, 2022

Resectable, Early-stage, NSCLC Trial in Worldwide (Durvalumab, Oleclumab, Monalizumab)

Completed

Resectable
+2 more

Durvalumab
+3 more

La Jolla, California
+17 more

Feb 23, 2022